2025 American College of Cardiology (Chicago) Samer Al Said – Bleeding with the FXI Inhibitor Abelacimab Compared with Rivaroxaban in Older Individuals-Analysis of the AZALEA-TIMI 71 Trial David Berg – Discovery and Validation of Plasma Renin and TNF-related apoptosis-inducing ligand (TRAIL) as Circulating Biomarkers of Heart Failure Risk in Patients with Type 2 Diabetes Mellitus Paul Haller – Evolocumab and complex coronary revascularization during 8-year follow-up-Analysis from the FOURIER and FOURIER OLE trials Paul Haller – Galectin-3 and Cardiovascular and Kidney Outcomes-Individual Patient Data Meta-Analysis of 74,358 Patients From 5 Multinational Clinical Trials Siddharth Patel – Factor XI Inhibition with Abelacimab in Atrial Fibrillation Across the Spectrum of Bleeding Risk Adam Ungemach – Early transfer to an advanced heart failure center is associated with improved outcomes Share this: Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Like this:Like Loading...
